Want to stay updated on the latest news?
Create a Reader Account today to follow the industries and companies that interest you, and customize your news dashboard. SIGN INTO READER ACCOUNT CREATE READER ACCOUNT
SHAREHOLDER ALERT: Barr Law Group Investigating GERN, MIE, CG, and EVF; Shareholders are Encouraged to Contact the Firm
April 27, 2021 04:36 ET
|
Barr Law Group
SAN DIEGO, April 27, 2021 (GLOBE NEWSWIRE) -- National law firm Barr Law Group is investigating the actions of the officers and board of directors of Geron Corporation, Cohen & Steers MLP Income...
Geron Corporation Reports Third Quarter 2020 Financial Results and Current Events
November 05, 2020 16:05 ET
|
Geron Corporation
FOSTER CITY, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported financial results for the third quarter ended...
Geron Receives Positive Opinion from the EMA Committee for Orphan Medicinal Products for Orphan Drug Designation in the European Union for Imetelstat to Treat Myelodysplastic Syndromes
July 01, 2020 08:30 ET
|
Geron Corporation
Designation would provide 10-year period of marketing exclusivity in the European Union after product approvalPatients are currently enrolling in a Geron-sponsored Phase 3 clinical trial in lower risk...
Geron Reports Four Imetelstat Data Presentations at Virtual Edition of the European Hematology Association (EHA) Annual Congress
June 12, 2020 08:30 ET
|
Geron Corporation
For the IMerge Phase 2 clinical trial, meaningful and durable transfusion independence reported with a new 1-year TI rate, indicating potential disease-modifying activity of imetelstat treatmentFor...
Geron Corporation Reports First Quarter 2020 Financial Results
May 28, 2020 16:05 ET
|
Geron Corporation
MENLO PARK, Calif., May 28, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported financial results for the first quarter ended March 31, 2020. The Company will host a conference...
Geron Corporation Announces the Closing of its Public Offering of Common Stock and Warrants
May 27, 2020 16:30 ET
|
Geron Corporation
MENLO PARK, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the closing of its previously announced...
Geron Corporation Announces the Pricing of its Public Offering of Common Stock and Warrants
May 22, 2020 07:15 ET
|
Geron Corporation
MENLO PARK, Calif., May 22, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the pricing of its previously announced...
Geron Corporation Announces Proposed Public Offering of Common Stock and Warrants
May 21, 2020 16:03 ET
|
Geron Corporation
MENLO PARK, Calif., May 21, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it intends to offer and sell shares of...
Geron Announces Plans for Imetelstat Phase 3 Clinical Trial in Myelofibrosis and Other Updates
May 21, 2020 16:01 ET
|
Geron Corporation
Geron plans to move forward with a Phase 3 clinical trial in refractory myelofibrosis (MF) with overall survival (OS) as a primary endpoint, which is expected to open for screening and enrollment in...
Geron to Present at Needham Virtual Healthcare Conference
April 08, 2020 16:30 ET
|
Geron Corporation
MENLO PARK, Calif., April 08, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, is scheduled to present a...